IDE196

DRUG2 trials

Sponsors

IDEAYA Biosciences

Conditions

Colorectal CancerCutaneous MelanomaMetastatic Uveal MelanomaOther Solid Tumors

Phase 1

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

RecruitingNCT03947385

IDEAYA BiosciencesColorectal Cancer, Cutaneous Melanoma, Metastatic Uveal Melanoma +1

Start: 2019-06-28End: 2027-06-15Target: 336Updated: 2026-06-08

Phase 2

IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

Active, not recruitingNCT05987332

IDEAYA BiosciencesMetastatic Uveal Melanoma

Start: 2023-10-31End: 2028-01-15Target: 420Updated: 2026-02-17

Related Papers

Darovasertib plus crizotinib vs investigator’s choice as first-line treatment for patients with HLA-A2 negative metastatic uveal melanoma: Primary results from the OptimUM-02 trial.

Journal of Clinical Oncology2026-06-03

Crizotinib and Darovasertib Significantly Reduce Metastatic Uveal Melanoma Cell Proliferation, Alone and In Combination

Open Research Europe2025-10-07

A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma

Frontiers in Oncology2023-06-099 citations

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

British Journal of Cancer2023-01-0954 citations

Abstract 1343: Preclinical evaluation of a PKC and MET inhibitor combination in metastatic uveal melanoma

Cancer Research2021-07-0110 citations

Abstract 4152: Preclinical evaluation of <i>PRKC</i> fusions and <i>GNA11/GNAQ</i> mutations as genetic drivers of PKC activation in non-MUM indications to support a phase 1/2 basket trial of IDE196

Cancer Research2020-08-151 citations